文献速递免疫规划

9-25岁人群人乳头瘤病毒疫苗与其他疫苗同时接种的免疫原性和安全性:系统综述与Meta分析

Immunogenicity and safety of human papillomavirus vaccine coadministered with other vaccines in individuals aged 9-25 years: A systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2019-12-10

该系统综述与Meta分析纳入13篇文献共11657名9-25岁健康参与者,评估人乳头瘤病毒(HPV)疫苗与其他常规疫苗同时接种的免疫原性和安全性。结果显示同时接种组与未同时接种组针对所有HPV型别的血清阳转率相同(合并RR=1.00,95%CI 1.00-1.00);二价HPV疫苗局部不良事件风险无显著差异(合并RR=1.00,95%CI 0.97-1.04),全身不良事件风险几乎相似(合并RR=1.10,95%CI 1.03-1.18);非二价HPV疫苗(四价和九价)同时接种组局部不良事件风险略高(合并RR=1.31,95%CI 1.17-1.47),全身不良事件风险更高(合并RR=2.09,95%CI 1.69-2.59)。作者认为同时接种其他疫苗与HPV疫苗是可接受的,且不干扰对HPV疫苗的免疫应答。

要点

  • 同时接种组与未同时接种组针对所有HPV型别的血清阳转率相同(合并RR=1.00,95%CI 1.00-1.00)。
  • 二价HPV疫苗同时接种组局部不良事件风险无显著差异(合并RR=1.00,95%CI 0.97-1.04),全身不良事件风险几乎相似(合并RR=1.10,95%CI 1.03-1.18)。
  • 非二价HPV疫苗(四价和九价)同时接种组局部不良事件风险略高(合并RR=1.31,95%CI 1.17-1.47),全身不良事件风险更高(合并RR=2.09,95%CI 1.69-2.59)。

核心结论

  • 作者认为其他疫苗与HPV疫苗同时接种是可接受的,且不干扰对HPV疫苗的免疫应答。
  • 同时接种有可能减少接种访视次数,从而提高依从性,进而更有效地预防疾病。

研究设计与样本

  • 系统综述与Meta分析,检索Medline/PubMed、EMBASE、Web of Knowledge截至2018年12月27日发表的文献。
  • 纳入13篇文献,共11657名9-25岁健康参与者。
  • 评估HPV疫苗与其他常规疫苗同时接种的免疫原性和安全性的合并相对危险度(RR)。

主要发现

  • 同时接种组与未同时接种组针对所有HPV型别(16、18、6、11、31、33、45、52和58型)的血清阳转率相同(合并RR=1.00,95%CI 1.00-1.00)。
  • 二价HPV疫苗同时接种组局部不良事件风险无显著差异(合并RR=1.00,95%CI 0.97-1.04),全身不良事件风险几乎相似(合并RR=1.10,95%CI 1.03-1.18)。
  • 非二价HPV疫苗(四价和九价)同时接种组局部不良事件风险略高(合并RR=1.31,95%CI 1.17-1.47),全身不良事件风险更高(合并RR=2.09,95%CI 1.69-2.59)。

关键数值与推荐

  • 针对所有HPV型别的血清阳转率:同时接种组与未同时接种组相同(合并RR=1.00,95%CI 1.00-1.00)。
  • 二价HPV疫苗局部不良事件风险:同时接种组与未同时接种组无显著差异(合并RR=1.00,95%CI 0.97-1.04)。
  • 二价HPV疫苗全身不良事件风险:同时接种组与未同时接种组几乎相似(合并RR=1.10,95%CI 1.03-1.18)。
  • 非二价HPV疫苗(四价和九价)局部不良事件风险:同时接种组略高(合并RR=1.31,95%CI 1.17-1.47)。
  • 非二价HPV疫苗(四价和九价)全身不良事件风险:同时接种组更高(合并RR=2.09,95%CI 1.69-2.59)。

临床怎么用

  • 作者认为其他疫苗与HPV疫苗同时接种是可接受的,且不干扰对HPV疫苗的免疫应答。
  • 同时接种有可能减少接种访视次数,从而提高依从性,进而更有效地预防疾病。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Adolescents and young adults are at a high risk of developing human papillomavirus (HPV) infections, which can be prevented with the use of vaccines. Moreover, a combined immunization strategy for administration of HPV vaccines with other routine vaccines may lead to better compliance. We aim to comprehensively evaluate immunogenicity and safety in the case of concomitantly administered HPV vaccine in individuals aged 9-25 years. METHODS: Relevant studies, published up to December 27, 2018, were identified through searches of Medline/PubMed, EMBASE, Web of Knowledge. The pooled relative risk (RR) of immunogenicity and safety information pertaining to the concomitant administration of HPV vaccines with other routine vaccines in healthy participants aged 9-25 years were evaluated. RESULTS: A total of 13 papers (11,657 participants) were included in this meta-analysis. The analyses showed that, between the concomitant and nonconcomitant administration groups, the seroconversion rate for the specific antibodies against all HPV types (type 16-, 18-, 6-, 11-, 31-, 33-, 45-, 52-, and 58) were the same (the pooled RR = 1.00, 95% confidence interval (CI) of 1.00-1.00); for the bivalent HPV (2vHPV) vaccine, the risks of local adverse events showed no significant difference (the pooled RR = 1.00, 95%CI: 0.97-1.04), and the risks of systemic adverse events were almost similar (the pooled RR = 1.10, 95% CI: 1.03-1.18); for the non-bivalent HPV (4vHPV and 9vHPV) vaccines, the risks of local adverse events were slightly higher in the concomitant administration groups (the pooled RR = 1.31, 95%CI: 1.17-1.47), and the risks of systemic adverse events were higher in the concomitant administration groups (the pooled RR = 2.09, 95% CI: 1.69-2.59). CONCLUSIONS: We believe that the concomitant administration of other vaccines along with HPV vaccine is acceptable and there is no interference with the immune response to HPV vaccine. Concomitant vaccine administration has the potential to minimize the number of vaccination visits, leading to increased compliance, hence more effective disease prevention.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Li Y, Zhu P, Wu M, et al. Immunogenicity and safety of human papillomavirus vaccine coadministered with other vaccines in individuals aged 9-25 years: A systematic review and meta-analysis. Vaccine. 2019. PMID: 31831220. doi:10.1016/j.vaccine.2019.10.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。